Thermo Fisher Scientific (TMO) Stock Overview
Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TMO Community Fair Values
Create NarrativeSee what 183 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Thermo Fisher Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$504.82 |
| 52 Week High | US$643.99 |
| 52 Week Low | US$385.46 |
| Beta | 0.95 |
| 1 Month Change | -18.82% |
| 3 Month Change | -12.77% |
| 1 Year Change | -5.08% |
| 3 Year Change | -9.81% |
| 5 Year Change | 5.42% |
| Change since IPO | 15,984.52% |
Recent News & Updates
Recent updates
Thermo Fisher: The Market Is Missing The Point, This Pullback Is A Buy (Rating Update)
Jan 30Unpleasant Surprises Could Be In Store For Thermo Fisher Scientific Inc.'s (NYSE:TMO) Shares
Jan 05
Risks To Shareholder Returns Are Elevated At These Prices For Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 01
Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In
Apr 24Thermo Fisher Scientific And Its Real Value
Apr 14The demand for personalized medicine will keep Thermo Fisher Scientific thriving
Resilient Demand for Life Sciences & Diagnostics – TMO is a key supplier for biotech, pharma, and research institutions, ensuring steady demand despite economic cycles.Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences
Mar 07Shareholder Returns
| TMO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -7.0% | -6.6% | -1.4% |
| 1Y | -5.1% | -5.4% | 10.9% |
Return vs Industry: TMO matched the US Life Sciences industry which returned -5.4% over the past year.
Return vs Market: TMO underperformed the US Market which returned 10.9% over the past year.
Price Volatility
| TMO volatility | |
|---|---|
| TMO Average Weekly Movement | 3.4% |
| Life Sciences Industry Average Movement | 7.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TMO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TMO's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 125,000 | Marc Casper | www.thermofisher.com |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
Thermo Fisher Scientific Inc. Fundamentals Summary
| TMO fundamental statistics | |
|---|---|
| Market cap | US$191.54b |
| Earnings (TTM) | US$6.70b |
| Revenue (TTM) | US$44.56b |
Is TMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMO income statement (TTM) | |
|---|---|
| Revenue | US$44.56b |
| Cost of Revenue | US$25.98b |
| Gross Profit | US$18.57b |
| Other Expenses | US$11.87b |
| Earnings | US$6.70b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 17.84 |
| Gross Margin | 41.68% |
| Net Profit Margin | 15.05% |
| Debt/Equity Ratio | 73.6% |
How did TMO perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 05:12 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Thermo Fisher Scientific Inc. is covered by 51 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kadambari Daptardar | Accountability Research Corporation |
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |